3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
45
Brain Neoplasms
28
Carcinoma, Non-Small-Cell Lung
27
Carcinoma, Hepatocellular
24
Neoplasm Metastasis
23
Lung Neoplasms
18
Pancreatic Neoplasms
14
Breast Neoplasms
12
Carcinoma, Renal Cell
11
Neoplasms
10
Sarcoma
7
Melanoma
7
Liver Neoplasms
7
Kidney Neoplasms
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Spinal Cord Neoplasms
3
Spinal Cord Compression
3
Small Cell Lung Carcinoma
3
Recurrence
3
Neuroma, Acoustic
3
Colonic Neoplasms
3
Radiation Injuries
2
Prostate Cancer Metastatic
2
Prostate Adenocarcinoma
2
Ovarian Neoplasms
2
Neoplasms, Second Primary
2
Klatskin Tumor
2
Hematologic Neoplasms
2
Interventions
blinatumomab
3
Blood Specimen Collection
2
Azacitidine
2
venetoclax
1
ivosidenib
1
gilteritinib
1
daratumumab
1
avapritinib
1
Transplantation
1
Radiosurgery
1
Neoadjuvant Therapy
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Lenalidomide
1
Interferon alpha-2
1
Inotuzumab Ozogamicin
1
Idarubicin
1
High-Throughput Nucleotide Sequencing
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
Consolidation Chemotherapy
1
Chemotherapy, Adjuvant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Neoplasm, Residual
×
Radiosurgery
×
Clear all
NCT01594892
2019-09-04
DOSIS
Wuerzburg University Hospital
Phase NA
Completed
60 enrolled